Blar i forfatter "Bolstad, Nils"

Viser treff 1-2 av 2

    • Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials 

      Jørgensen, Kristin Kaasen; Goll, Guro Løvik; Sexton, Joe; Bolstad, Nils; Olsen, Inge C.; Asak, Øivind Wessel; Berset, Ingrid Prytz; Blomgren, Ingrid; Dvergsnes, Katrine; Florholmen, Jon; Frigstad, Svein Oskar; Henriksen, Magne; Hagfors, Jon; Huppertz-Hauss, Gert; Haavardsholm, Espen Andre; Klaasen, Rolf Anton; Moum, Bjørn; Noraberg, Geir; Prestegård, Ulf; Rydning, Jan Henrik; Sagatun, Liv; Seeberg, Kathrine; Torp, Roald; Vold, Cecilia; Warren, David J.; Ystrøm, Carl Magnus; Lundin, Knut Erik Aslaksen; Kvien, Tore Kristian; Jahnsen, Jørgen (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-09-23)
      <i>Background</i> - The NOR-SWITCH main and extension trials demonstrated that switching from originator to biosimilar infliximab (CT-P13) is efficacious and safe across six diseases. However, a subgroup analysis of Crohn’s disease (CD) in the main trial displayed a close to significant difference favouring originator infliximab, and more scientific data have therefore been requested.<p><p> <i> ...

    • Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study 

      Ueland, Thor; Gullestad, Lars; Kou, Lei; Aukrust, Pål; Anand, Inder S.; Nordlund, Marianne Sparby; McMurray, John J.; van Veldhuisen, Dirk J.; Warren, David; Bolstad, Nils (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-08-25)
      <p><i>Aims</i>: Neuroendocrine activation is associated with poor outcome in heart failure (HF). The neuropeptide gastrin‐releasing peptide (GRP), derived from the precursor proGRP1‐125 (proGRP), has recently been implicated in inflammation and wound repair. We investigated the predictive value of proGRP on clinical outcomes in HF patients with reduced ejection fraction.</p> <p><i>Methods and ...